Skip to main content

Table 3 Baseline comparison between patients according to inactive disease criteria (ASDAS – CRP < 1.3)

From: Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

 

ASDAS CRP < 1.3 (n = 31)

ASDAS CRP ≥ 1.3 (n = 49)

P

Male gender

27/31 (87.1%)

39/49 (79.6%)

0.548

HLA-B27 positivity

20/27 (74.1%)

37/42 (88.1%)

0.193

Smoking

4/25 (16.0%)

19/41 (46.3%)

0.016*

Baseline:

 Age, years

32.3 ± 9.9

39.8 ± 11.8

0.004*

 Duration of disease, years

10.6 ± 9.3

14.7 ± 9.8

0.047*

Co-medication:

 NSAID

23/31 (74.2%)

35/49 (71.4%)

1.000

 DMARD

27/31 (87.1%)

37/49 (75.5%)

0.259

 MTX

11/31 (35.5%)

21/49 (42.9%)

0.640

 SSZ

22/31 (70.9%)

22/49 (44.9%)

0.037*

 BASDAI

4.6 ± 2.2

5.8 ± 2.0

0.027*

 BASFI

4.4 ± 2.0

6.2 ± 2.5

0.003*

 BASMI

3.6 ± 2.8

5.0 ± 2.7

0.034*

 ASQol

10.6 ± 5.6

11.2 ± 4.8

0.669

 ASDAS – CRP

3.5 ± 0.9

3.9 ± 1.0

0.126

 CRP (mg/L)

20.3 (9.7, 36.7)

24.6 (14.9, 38.9)

0.664

 ESR (mm/h)

23.0 (10.3, 32.0)

21.0 (12.5, 36.5)

0.650

 1st anti-TNF retention

22/31 (71.0%)

23/49 (46.9%)

0.040*

 Last anti-TNF treatment, weeks

176.9 ± 85.2

182.1 ± 106.2

0.820

  1. Values are expressed as mean (SD), median (quartile) and percentages. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, ASQoL Ankylosing Spondylitis Quality of Life, CRP C Reactive Protein, ESR Erythrocyte Sedimentation Rate, ASDAS Ankylosing Spondylitis Disease Activity Score, DMARD Disease Modifying Antirheumatic Drug, NSAID Non-steroidal Anti-Inflammatory Drug, SSZ Sufasalazine, MTX Methotrexate, *P < 0.05